LB Pharmaceuticals LBRX
LB Pharmaceuticals (Nasdaq: LBRX) is a CNS/neurology/psychiatry drug developer. Its lead program, LB-102, is in Phase 3 for Schizophrenia. Its next catalyst on record is LB-102 for negative symptoms of schizophrenia: Update on potential trial design (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LB-102 for negative symptoms of schizophrenia — Update on potential trial design (Q1 2027). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LB-102 | Schizophrenia | small molecule | Phase 3 |
| LB-102 | Bipolar depression | small molecule | Phase 2 |
| LB-102 | Adjunctive treatment in major depressive disorder (aMDD) | small molecule | Phase 2 |
| LB-102 | Negative symptoms of schizophrenia | small molecule | Pre-clinical |
| LB-102 | Alzheimer's disease agitation/psychosis | small molecule | Pre-clinical |
| LB-102 LAI | Schizophrenia and bipolar disorder (long-acting injectable) | small molecule | Pre-clinical |
Recent results and decisions
- Mar 1, 2026started Pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia was initiated in March 2026, topline data expected 2H 2027.
Initiated the pivotal Phase 3 (NOVA-2) trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia in March 2026, with topline data expected in the second half of 2027.
Filing - Jan 1, 2026started Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar 1 depression was initiated in January 2026, topline data expected Q1 2028.
Initiated the Phase 2 trial (ILLUMINATE-1) evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression in January 2026, with topline data expected in the first quarter of 2028.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.